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ABSTRACT
Objective To assess if authors of randomised clinical
trials convey the fact that they have used surrogate
outcomes and discussed their validity.
Design Cohort study.
Setting Six major general medical journals.
ParticipantsRandomisedclinicaltrialspublishedin2005
and 2006 that used a surrogate as a primary outcome.
Results Of 626 published randomised clinical trials, 109
(17%) used a surrogate as a primary outcome. Of these
trials, 62 (57%, 95% confidence interval 47% to 67%)
clearly reported that the primary outcome was a
surrogate.Only38(35%,26%to45%)alsodiscussedthe
validity of the surrogate.
ConclusionOnlyaboutonethirdofauthorsofrandomised
clinical trials that used a surrogate as a primary outcome
reported adequately on the surrogate. Better reporting is
needed.
INTRODUCTION
Surrogateoutcomesmayseemanattractivealternative
to clinically relevant outcomes in clinical trials.
1 The
reasons for this are that there may be more events
and that the surrogate may occur faster or be easier to
assess, thereby shortening a trial and sometimes mak-
ing it more ethically acceptable.
23Surrogate outcomes
are, however, associated with many problems. The
main one arises when the intervention causes a “posi-
tive” response on the surrogate but has no effect, or a
harmful effect, on the clinical outcome, or vice versa.
Such discrepancies can lead to implementation of
harmful treatments or to exclusion of beneficial inter-
ventions.
A surrogate outcome has been defined as “a labora-
tory measurement or a physical sign used as a substi-
tute for a clinically meaningful outcome that measures
directly how a patient feels, functions or survives.”
1
Examples are high cholesterol concentrations for
mortality,
3 glycated haemoglobin for complications
from diabetes,
4 or CD4 cell counts for AIDS related
morbidity.
3 These measures are all considered to be
in the causal pathway for the clinical outcome. Some-
times, however, the surrogate may not be causally or
stronglyrelatedtotheclinicaloutcome,butonlyacon-
comitant factor, and thus may not predict the effect on
the clinical outcome.
3
Some criteria influence the validity of a surrogate
outcome: if the surrogate has been shown to be in the
causal pathway, it is considered biologically
plausible
13; if a correlation has been established
between the surrogate and the clinical outcome (for
example, in observational studies)
135; and if one or,
even better, many randomised trials on similar drug
classes have established that the intervention’s effect
on the surrogate captures the intervention’s effect on
the clinical outcome.
1 Several statistical methods are
used to assess these criteria and if they are fulfilled the
validity of the surrogate is increased.
5 However, even
trials with thoroughly validated surrogates cannot
match trials with clinical outcomes, as some uncer-
tainty will always remain. Therefore results from trials
basedonsurrogatescanbedifficultfordoctorstoapply
in clinical practice.
Clinicians, and particularly pharmaceutical compa-
nies,oftendonotdistinguishclearlybetweensurrogate
and clinical outcomes. It is therefore important that
clinical trialists report whether they have used a surro-
gate and convey this information to the readers.
Furthermore,readerswillwanttoknowifthesurrogate
has been validated and is sufficiently reliable to war-
rant changes in clinical practice, provided the harms
of the treatment are acceptable.
We evaluated if authors of randomised clinical trials
convey the fact that they have used a surrogate as a
primary outcome and have discussed the surrogate’s
validity. Manuscripts that reported on both were clas-
sified as adequate.
METHODS
We searched for all randomised clinical trials pub-
lished in 2005 and 2006 in JAMA, New England Journal
of Medicine, Lancet, BMJ, Annals of Internal Medicine, and
PLoS Medicine. We chose these publications as they are
broad journals with high clinical impact and their arti-
cles are easy to retrieve. We searched for the journal
namesthroughPubMed,limitingthesearchto“rando-
mised controlled trials” and publication in 2005 and
2006.
We included only randomised clinical trials that
used a surrogate as a primary outcome. An outcome
was classified as a surrogate if it did not directly mea-
sure how a patient feels, functions, or survives—for
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or results of a urine dipstick test.
Some subjectivity is involved in judging whether an
outcome is truly a surrogate. All borderline cases were
discussedamongtheauthors,andonlyifallagreedwas
the outcome classified as a surrogate. We excluded
trials that had used a primary clinical outcome (for
example, mortality, nausea, daily function skills),
those with a composite outcome if one or more of the
individual outcomes were clinical, and those that had
cost as a primary outcome.
Data extraction
We extracted data on characteristics of the trial and
authors’ comments. Trial characteristics included type
of surrogate, journal source, main clinical area, sample
size, length of follow-up, type of sponsor (for profit,
mixedfunding,ornon-profit),
6andwhethertheexperi-
mentalinterventionwasrecommendedforclinicaluse.
6
Authors’ comments included whether the authors:
(1) reported that they had used a surrogate outcome
—for example, the outcome was labelled as a “surro-
gate outcome,”“ intermediate outcome,” or “non-clin-
ical outcome,” or it was clearly understood in the
contextofthe articlethatthe outcomewasa surrogate;
and(2)reportedonthesurrogate’svalidity—forexam-
ple, it was mentioned whether the surrogate outcome
was considered validated or not validated, or the level
ofassociation,relation,orconnectionbetweenthesur-
rogate and clinical outcomes were discussed.
Wenotedonlywhattheauthorsreportedinthepub-
licationonvalidityofthesurrogates.Wedidnotassess
the methods used for validation of the outcomes.
Statistical analyses
Our two main outcomes (reporting on use of a surro-
gate outcome and of its validity) are presented as pro-
portions with 95% confidence intervals.
We explored if there was an association between
authors reporting adequately and type of sponsor (for
profit versus mixed funding and non-profit pooled
together), and whether the treatment was recom-
mended for clinical use. Exploratory analyses were
carried out using Fisher’s exact test, with P<0.05 con-
sidered significant.
Procedure
One researcher (JLC) screened all abstracts and
excluded those clearly reporting the use of a primary
clinical outcome. For the remaining abstracts the full
article was retrieved and assessed for eligibility. If no
primary outcome was specified, we regarded the out-
come used to estimate sample size as primary. We
included trials with a surrogate used as a primary out-
come.Datawereextractedbyoneresearcher(JLC)and
entered into Excel sheets based on experience from a
pilot study. JB or PG reassessed all extracted data. Dis-
agreements about eligibility or data were resolved by
discussion between all three authors. In case of no con-
sensus on eligibility, we excluded the trial.
RESULTS
Overall, 626 citations were identified. Of these, 513
were excluded: 486 did not use a surrogate as a pri-
mary outcome, 17 were not randomised clinical trials,
and10assessedcost(figure).Fouroftheremaining113
trials were excluded after discussions among the
authors, leaving 109 eligible trials (17% of all rando-
mised clinical trials from the included journals). The
table shows the characteristics of the included trials.
In 62 of the 109 trials (57%, 95% confidence interval
47% to 67%)
w1-w109 the authors clearly conveyed that
they had used a surrogate as a primary outcome: for
example, “We selected a surrogate outcome, com-
monly used in studies of contrast induced
nephropathy”
7 and “Trial outcomes were cardio-vas-
cular disease risk factors, not clinical events.”
8
Of these 62 trials, 38 (61%, 53% to 69%) discussed if
their surrogate was validated or not: for example, “The
measurement of carotid intima-media thickness is
among the best validated of these surrogate end
points”
9 and “The relationship between efficacy mea-
sures assessed with the use of intravascular ultrasono-
graphy and clinical outcomes has not been fully
explored.”
10 Accordingly, a total of 38 trials (35%, 26%
to 45%) reported adequately on surrogate outcomes.
Thirty three trials (30% of total) were sponsored by
forprofitorganisations.Fifteenofthese(45%)reported
adequatelyonsurrogates—thatis,reportedonboththe
use of and the validity of the surrogate. Seventy six
trials (70% of total) were sponsored, 45 (59%) by
mixed sponsors and 31 (41%) by non-profit organisa-
tions. Twenty three (30%) trials sponsored by non-
profit organisations or mixed sponsors reported ade-
quatelyonsurrogates.Trialsfundedby forprofitorga-
nisations were not significantly more likely to report
inadequately on surrogates than trials funded by non-
profitorganisations(relativerisk0.67,95%confidence
interval 0.40 to 1.10).
The authors recommended the experimental inter-
vention in 29 trials (27% of total). Of these, six trials
(21%) reported adequately on surrogates. Eighty of
the trials (73% of total) did not recommend the
Initial sample of abstracts (n=626)
Full text article retrieved (n=309)
Eligible after review by JLC (n=113)
Eligible for study (n=109)
Total excluded after discussion with coauthors (n=4)
Total excluded (n=317):
  A primary clinical outcome (n=305)
  Not a randomised clinical trial (n=2)
  Trial assessed cost (n=10)
Total excluded (n=196):
  A primary clinical outcome (n=181)
  Not a randomised clinical trial (n=15)
Selection of trials
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quately on surrogates. Trials reporting inadequately
on surrogates were not significantly more likely to
recommend the intervention than trials reporting ade-
quately on surrogates (1.93, 0.90 to 4.14).
DISCUSSION
One in five randomised clinical trials published in six
general major medical journals during 2005 and 2006
used a surrogate as a primary outcome. Of these, only
onethirdreportedadequatelythattheyhadusedasur-
rogate and discussed the surrogate’s validity. In con-
trast with our hypothesis, we did not find that trials
sponsored by for profit organisations or trials that
recommended the experimental intervention were
morelikelytoreportinadequatelyonsurrogates.How-
ever,ourstudyhadlimitedpowerforthiscomparison.
Strengths and weaknesses of the study
We assessed all published randomised clinical trials
(n=626) during two years in six major general medical
journals. We chose these journals because they have a
high impact on clinical decisions and because they do
not focus on a single discipline of medicine such as
journals oriented to a particular specialty. Hence the
readers cannot be expected to have prior knowledge
about surrogates beyond their clinical area, which
strengthens the need to mention when a surrogate has
been used and to discuss its validity.
Only one researcher screened all trial abstracts for
eligibility. This may have led to a few relevant trials
that used borderline surrogates being overlooked, but
clear cut cases were not likely to have been missed.
Two authors independently assessed the trials for
final inclusion. Four trials were excluded because no
consensus was reached. This raises the possibility that
the prevalence of trials using surrogate outcomes is
marginally higher than our finding.
Two authors independently extracted data to mini-
mise the risk of errors. For seven trials, disagreements
occurred about whether the authors had reported ade-
quately on the use of a surrogate or its validation, but
consensus was obtained through discussion.
It is not always clear whether trialists report ade-
quatelyonthe use and the validityofsurrogates.Some-
times it is conveyed in the context of the publication—
forexample,“thoughwhethersuchasmalldifferenceis
clinically relevant is doubtful.”
11 In this example, the
validity of the surrogate was not reported directly, but
the authors did clearly state that the benefit shown on
the surrogate did not necessarily translate into clinical
benefit.Insuchcases,weerredontheconservativeside
and classified the study as showing adequate reporting.
Comments on results
To our knowledge, this is the first study to assess the
extenttowhichsurrogateoutcomesareused.However,
the number of included trials was moderate. Given the
shortcomings of surrogates it is surprising that they are
used as primary outcomes in about one fifth of pub-
lished randomised clinical trials. One reason may be
the involvement of for profit organisations in many
trials. These organisations have an interest in using sur-
rogate outcomes, as it shortens the trial, makes it less
costly, and speeds up the implementation of new inter-
ventions.Also,trialistsmaynotconsideriftheoutcome
supportswhatthetrialaimstoclarifyandmaytherefore,
inappropriately,chooseasurrogateasaresultoflackof
guidanceontrialdesign.Otherreasonsforthe frequent
use of surrogates are that the trial is small owing to lack
of adequate resources, the trial is only hypothesis gen-
erating, the surrogate is truly validated (although this
canalmostalwaysbedisputed),ortheclinicaloutcomes
are impossible to assess owing to ethical or practical
reasons. We did not investigate whether or not the use
of surrogates was justified in the included trials.
That about only one third of all trials report ade-
quately on both the use of a surrogate and its validity
is notable, especially considering how little it takes to
be phrased: “compared with glimepiride, pioglitazone
reduced carotid artery intima-media thickness pro-
gression, a validated surrogate end point for coronary
Characteristics of included randomised clinical trials that
used a surrogate as primary outcome
Characteristics No (%) of trials
Journal source:
New England Journal of Medicine 45 (41)
Lancet 21 (19)
JAMA 18 (17)
Annals of Internal Medicine 13 (12)
BMJ 10 (9)
PLoS Medicine 2 (2)
Clinical area:
Cardiovascular 27 (25)
Infectious disease 20 (18)
Endocrinology 13 (12)
Gastrology and hepatology 11 (10
Pulmonology 8 (7)
Obstetrics 7 (6)
Nephrology and urology 5 (5)
Oncology 4 (4)
Neurology 3 (3)
Other 11 (10)
Sample size:
0-100 17 (16)
>100-300 30 (28)
>300-1000 41 (38)
>1000-5000 17 (16)
>5000 4 (4)
Type of surrogate:
Blood sample 40 (37)
Imaging 27 (25)
Lung function 6 (5)
Other 36 (32)
Length of follow-up:
0-30 days 13 (12)
>30 days-6 months 33 (30)
>6 months-1 year 29 (27)
>1 year 34 (31)
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4 Reasons for
inadequate reporting may be that authors do not con-
sider it important, focus and guidance on this issue is
minimal, or the statistical validation of surrogates is
considered complicated.
5 We would expect less ade-
quate reporting on surrogates in small specialty jour-
nals, in part because the use of certain surrogates has
been tacitly assumed to be adequate. Therefore, in the
opinion of some editors and peer reviewers, authors
are not required to mention that the outcome is a sur-
rogate and discuss its validity in every manuscript.
To improve reporting on surrogates, journal editors
couldguideauthorsintheirinstructionstoauthors,and
there could be guidance on surrogates in the CON-
SORT (Consolidated Standards of Reporting Trials)
statement to which many journals refer.
1213
Problems in defining an outcome as clinical or surrogate
Defining anoutcome asclinical or surrogate can be dif-
ficult.Forexample,“lengthofstayinhospital”
14isintui-
tively a surrogate outcome for morbidity but might be
perceived by some patients and clinicians as a clinical
outcome. Furthermore, some patients may argue that
they get the best treatment and support at the hospital
whereas others prefer home care. Thus, this outcome
may not measure directly how patients feel and it is dif-
ficult to classify solely as clinical or surrogate.
Another example is incidence of cancer,
15 which
dependingonstudydesigncanbeclinicalorsurrogate.
Thediagnosiscancerwillaffecthowapatientfeelsand
itisthereforeaclinicaloutcomeinmosttrials.Conver-
sely, the incidence of cancer is a predictor of mortality
and can be used as a substitute measure (surrogate) for
this clinical outcome in some trials. Thus to classify an
outcome as surrogate or clinical trialists need to be
aware of what the trial aims to clarify.
Yet another example concerns the ambiguity in
determining the cut off for a clinically relevant out-
come when dealing with continuous scales. Postpar-
tum haemorrhage is defined as a blood loss of 500 ml
ormore.
16Itseemsobviousthatthehighertheamount
of blood loss, the higher the risk of morbidity, but is
500 ml clinically relevant? If the blood loss makes the
patient afraid, is it then a clinical measure? Or should
we choose a cut-off point that reflects when blood loss
becomes life threatening? Haemorrhage illustrates the
problems with using apparently clinical outcomes
measured on continuous scales, as it may be difficult
toassesstheclinicalrelevanceandclassifytheoutcome
as clinical or surrogate.
Validation
Ingeneralitisnotsufficienttoensurethatthesurrogate
and the clinical outcome are correlated.
17 Ideally, sur-
rogates used in randomised clinical trials should cap-
ture the full effect of the intervention on the clinical
outcome, and all effects of the intervention should be
mediated through or captured by the surrogate.
518
However, even trials based on validated surrogates
may not be able to capture unexpected important
harmful effects of the intervention. Thus, even in
cases with apparently validated surrogates, challenges
are faced. Glycated haemoglobin is considered a sur-
rogate of cardiac events in type 2 diabetes. Accord-
ingly, lowering the HbA1c level reduces the risk of
cardiac events. However, recently a randomised clin-
ical trial on rosiglitazone (Avandia; GlaxoSmithKline)
found that the drug lowered HbA1c levels but
increased the composite risk of myocardial infarction,
angina, or sudden death.
19 This illustrates that even
though a surrogate has been validated for one drug
and one clinical outcome, it is not automatically valid
for other drugs or clinical outcomes. As with clinical
interventions, surrogates that have undergone valida-
tion through a meta-analysis approach are more reli-
ablethanothersurrogates.
15However,eventrialswith
thoroughly validated surrogates can never be as reli-
able as trials using clinical outcomes.
Approval on the basis of surrogates
In Europe and the United States new drugs can be
approved for commercial use without having shown
effects on clinical outcomes. The European Medi-
cines Agency has no specific regulations for this but
has guidelines for new drugs, which state that a posi-
tive benefit-risk balance is a key requirement to
obtain a marketing authorisation in the European
Union. This process generally lacks transparency.
New drugs can be approved by the US Food and
Drug Administration without having shown effects
on clinical outcomes, through the accelerated
approval programme used for serious illness: “FDA
maygrantmarketingapprovalforanewdrugproduct
on the basis of adequate and well-controlled clinical
trials establishing that the drug product has an effect
on a surrogate endpoint that is reasonably likely,
based on epidemiologic, therapeutic, pathophysiolo-
gic...”orotherevidence,topredictclinicalbenefit.
20
It was through this process that rosiglitazone was
approved,asHbA1cwasconsideredreasonablylikely
to predict mortality. This highlights the uncertainty
related to approval of drugs based on surrogate out-
comes. In the case of serious illnesses where no good
treatments exist, these procedures may seem
WHAT IS ALREADY KNOWN ON THIS TOPIC
A surrogate outcome can sometimes be a relevant substitute for a clinically meaningful
outcome in randomised trials
Uncritical use of surrogate outcomes can be misleading and has resulted in implementation
of harmful interventions
N ewdr ug sc anbeap pr ov edfo rc om me r cia lus einEu ro pean dth eUn it edSt at esonth eba si s
of surrogate outcomes
WHAT THIS STUDY ADDS
Surrogate outcomes are often used as main outcomes in randomised trials
Only one third of authors of randomised clinical trials that use surrogate outcomes report
adequately on the surrogate.
Better reporting on surrogates is needed to avoid misleading conclusions and uncritical
acceptance of new treatments
RESEARCH
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clinically effective similar drugs are on the market,
however, it is important to make sure that evidence
on clinical outcomes (both benefits and harms) is suf-
ficient before marketing a new drug.
Conclusion
Our study shows that about one in five published ran-
domisedclinicaltrialsusesurrogateoutcomesandthat
only one third of these report that they have used a
surrogate and discuss its validity. Thus readers should
be aware of conclusions in randomised clinical trials
that are based on hidden surrogates. Better reporting
on surrogates might reduce unwarranted conclusions
and uncritical acceptance of new treatments.
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